Literature DB >> 2968776

Monoclonal antibody analysis of mononuclear cells in myopathies. V: Identification and quantitation of T8+ cytotoxic and T8+ suppressor cells.

K Arahata1, A G Engel.   

Abstract

In polymyositis (PM) and inclusion body myositis (IBM), but not in dermatomyositis there is evidence of cell-mediated cytotoxicity: T8+ cells accompanied by macrophages focally surround, invade, and destroy nonnecrotic muscle fibers. However, the T8 marker appears on both cytotoxic (Tc) and suppressor (Ts) cells. The Leu-15 marker appears on Ts but not on Tc cells, but it also appears on macrophages and on some killer/natural killer cells. To obviate this problem, the T8, Leu-15, and Leu-7 markers were demonstrated by sequential paired immunofluorescence in single cryostat sections. Using this approach, we reliably differentiated for the first time between Tc and Ts cells in tissue sections. Six cell phenotypes were identified: T8+ Leu-15-Leu7- Tc cells, T8+ Leu-15+ Leu-7- Ts cells, three types of Leu-7+ killer/natural killer cells, and T8-Leu-15+ Leu-7- macrophages. Muscle specimens from 5 patients with PM and 5 with IBM were studied. In each case, 6 nonnecrotic muscle fibers focally surrounded and invaded by mononuclear cells were selected randomly. A total of 2,022 mononuclear cells were analyzed, 870 from patients with PM and 1,152 from those with IBM. When counts of the identified cell phenotypes in individual patients were pooled, there were four times as many T8+ Leu-15- Leu-7- Tc cells as T8+ Leu-15+ Leu-7- Ts cells in either PM or IBM samples. However, when the relative frequencies of the Tc and Ts cells were examined in individual patients, the Tc cells tended to become more abundant, and the Ts cells correspondingly less abundant, with the duration of symptoms.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2968776     DOI: 10.1002/ana.410230511

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  22 in total

1.  ANT1 is reduced in sporadic inclusion body myositis.

Authors:  E Barca; M Aguennouz; A Mazzeo; S Messina; A Toscano; G L Vita; S Portaro; D Parisi; C Rodolico
Journal:  Neurol Sci       Date:  2012-02-21       Impact factor: 3.307

2.  Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement.

Authors:  N A Goyal; T M Cash; U Alam; S Enam; P Tierney; N Araujo; F H Mozaffar; A Pestronk; T Mozaffar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-04-09       Impact factor: 10.154

3.  Mechanisms of cell-mediated myocytotoxicity in the peripheral blood of patients with inflammatory myopathies.

Authors:  I Bank; A F Miranda; L Chess
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

4.  Expression of granulysin in polymyositis and inclusion-body myositis.

Authors:  K Ikezoe; S Ohshima; M Osoegawa; M Tanaka; K Ogawa; K Nagata; J-i Kira
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10       Impact factor: 10.154

5.  Inflammatory and non-inflammatory inclusion body myositis. Characterization of the mononuclear cells and expression of the immunoreactive class I major histocompatibility complex product.

Authors:  D Figarella-Branger; J F Pellissier; N Bianco; B Devictor; M Toga
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 6.  Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2018-07-23       Impact factor: 3.598

Review 7.  Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.

Authors:  E M Moran; F L Mastaglia
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

8.  MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies.

Authors:  E Bartoccioni; S Gallucci; F Scuderi; E Ricci; S Servidei; A Broccolini; P Tonali
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

9.  Soluble CD4, CD8 in patients with polymyositis/dermatomyositis.

Authors:  Y Tokano; T Obara; H Hashimoto; K Okumura; S Hirose
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

Review 10.  Inflammation induced loss of skeletal muscle.

Authors:  Priya Londhe; Denis C Guttridge
Journal:  Bone       Date:  2015-11       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.